US6168778B1
(en)
|
1990-06-11 |
2001-01-02 |
Nexstar Pharmaceuticals, Inc. |
Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
|
US6248722B1
(en)
*
|
1995-08-29 |
2001-06-19 |
Sumitomo Pharmaceuticals Company, Limited |
Medicament comprising HGF gene
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US6426335B1
(en)
|
1997-10-17 |
2002-07-30 |
Gilead Sciences, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
US20030229040A1
(en)
*
|
1997-03-21 |
2003-12-11 |
Georgetown University |
Cationic liposomal delivery system and therapeutic use thereof
|
US6126965A
(en)
*
|
1997-03-21 |
2000-10-03 |
Georgetown University School Of Medicine |
Liposomes containing oligonucleotides
|
US7262173B2
(en)
*
|
1997-03-21 |
2007-08-28 |
Georgetown University |
Chemosensitizing with liposomes containing oligonucleotides
|
US6528271B1
(en)
|
1997-06-05 |
2003-03-04 |
Duke University |
Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
|
DE69826697T2
(de)
|
1997-07-07 |
2006-02-16 |
Medical Research Council |
In vitro selektionsmethode
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US6083923A
(en)
*
|
1997-10-31 |
2000-07-04 |
Isis Pharmaceuticals Inc. |
Liposomal oligonucleotide compositions for modulating RAS gene expression
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6277893B1
(en)
|
1999-05-10 |
2001-08-21 |
National Starch & Chemical Co. Investment Holding Corporation |
Polysaccharide and dimethicone copolyol as emulsifier for cosmetic compositions
|
AU6918100A
(en)
*
|
1999-08-25 |
2001-03-19 |
Georgetown University |
Delivery system for therapy comprising hollow seeds, preferably metal, and use thereof
|
WO2001026694A1
(fr)
|
1999-10-08 |
2001-04-19 |
Medgene Bioscience, Inc. |
Therapie genique pour cardiomyopathie
|
EP1142590B8
(de)
*
|
1999-10-29 |
2008-11-26 |
AnGes MG, Inc. |
Gentherapie für diabetische ischämie
|
WO2001041739A2
(en)
*
|
1999-12-13 |
2001-06-14 |
Lipoxen Technologies Limited |
Liposomes
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
CA2425092A1
(en)
*
|
2000-10-06 |
2002-04-11 |
Michael F. Holick |
Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules
|
US7279324B2
(en)
|
2001-01-23 |
2007-10-09 |
Duke University |
Nucleic acid encoding G-protein coupled receptor with modified DRY motif
|
WO2002059337A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Georgetown University School Of Medicine |
Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
|
EP2270024B1
(de)
|
2001-06-21 |
2018-10-24 |
Ionis Pharmaceuticals, Inc. |
Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
|
AUPR621501A0
(en)
|
2001-07-06 |
2001-08-02 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of ds rna
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ577565A
(en)
|
2001-10-09 |
2010-10-29 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP1380289A1
(de)
*
|
2002-07-10 |
2004-01-14 |
Denis Bron |
Verabreichungsform für pharmazeutische Agenzien
|
MXPA05002791A
(es)
|
2002-09-13 |
2005-12-05 |
Replicor Inc |
Oligonucleotidos antivirales complementarios sin secuencia.
|
AU2003278957A1
(en)
|
2002-09-26 |
2004-04-23 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
ES2420914T3
(es)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
US8980310B2
(en)
*
|
2002-12-31 |
2015-03-17 |
Bharat Serums and Vaccines, Ltd. |
Non-pegylated long-circulating liposomes
|
US20060078893A1
(en)
|
2004-10-12 |
2006-04-13 |
Medical Research Council |
Compartmentalised combinatorial chemistry by microfluidic control
|
GB0307428D0
(en)
|
2003-03-31 |
2003-05-07 |
Medical Res Council |
Compartmentalised combinatorial chemistry
|
GB0307403D0
(en)
|
2003-03-31 |
2003-05-07 |
Medical Res Council |
Selection by compartmentalised screening
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
EP1547581A1
(de)
*
|
2003-12-23 |
2005-06-29 |
Vectron Therapeutics AG |
Liposomaler Impstoff für die Behandlung von menschlichen hematologischen mlignen Erkrankungen
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
US20050221339A1
(en)
|
2004-03-31 |
2005-10-06 |
Medical Research Council Harvard University |
Compartmentalised screening by microfluidic control
|
US7968287B2
(en)
|
2004-10-08 |
2011-06-28 |
Medical Research Council Harvard University |
In vitro evolution in microfluidic systems
|
US20060211004A1
(en)
|
2005-02-15 |
2006-09-21 |
Ilsley Diane D |
Methods and compositions for determining non-specific cytotoxicity of a transfection agent
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
WO2007053696A2
(en)
|
2005-11-01 |
2007-05-10 |
Alnylam Pharmaceuticals, Inc. |
Rnai inhibition of influenza virus replication
|
AU2006308765B2
(en)
|
2005-11-02 |
2013-09-05 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
WO2007081387A1
(en)
|
2006-01-11 |
2007-07-19 |
Raindance Technologies, Inc. |
Microfluidic devices, methods of use, and kits for performing diagnostics
|
US7718629B2
(en)
|
2006-03-31 |
2010-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 gene
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
EP2047910B1
(de)
|
2006-05-11 |
2012-01-11 |
Raindance Technologies, Inc. |
Mikrofluidische Vorrichtung und Verfahren
|
US9562837B2
(en)
|
2006-05-11 |
2017-02-07 |
Raindance Technologies, Inc. |
Systems for handling microfludic droplets
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
AU2007253677B2
(en)
|
2006-05-22 |
2011-02-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
EP3536396B1
(de)
|
2006-08-07 |
2022-03-30 |
The President and Fellows of Harvard College |
Fluorkohlenstoffemulsionsstabilisierende tenside
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
WO2008097559A2
(en)
|
2007-02-06 |
2008-08-14 |
Brandeis University |
Manipulation of fluids and reactions in microfluidic systems
|
EP2905336A1
(de)
|
2007-03-29 |
2015-08-12 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression eines Gens von Ebola
|
US8592221B2
(en)
|
2007-04-19 |
2013-11-26 |
Brandeis University |
Manipulation of fluids, fluid components and reactions in microfluidic systems
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
CA2707042A1
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
JP5697988B2
(ja)
|
2007-12-27 |
2015-04-08 |
プロチバ バイオセラピューティクス インコーポレイティッド |
干渉rnaを使用したポロ様キナーゼ発現のサイレンシング方法
|
JP2011518117A
(ja)
|
2008-03-05 |
2011-06-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Eg5およびVEGF遺伝子の発現を阻害するための組成物および方法
|
WO2009129319A2
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Silencing of csn5 gene expression using interfering rna
|
US20110076296A1
(en)
|
2008-04-25 |
2011-03-31 |
Innate Pharma S.A. |
TLR3 Agonist Compositions
|
EP2315629B1
(de)
|
2008-07-18 |
2021-12-15 |
Bio-Rad Laboratories, Inc. |
Tröpfchenbibliotheken
|
CN103429270B
(zh)
|
2008-08-25 |
2016-11-23 |
埃克斯雷德制药有限公司 |
阻止结缔组织生长因子的反义核苷酸及其用途
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
EP2344639B1
(de)
|
2008-10-20 |
2015-04-22 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der transthyretinexpression
|
WO2010060104A2
(en)
|
2008-11-24 |
2010-05-27 |
Moma Therapeutics |
Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration
|
NZ593618A
(en)
|
2008-12-10 |
2013-02-22 |
Alnylam Pharmaceuticals Inc |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
JP6032724B2
(ja)
|
2009-03-12 |
2016-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法
|
EP2411148B1
(de)
|
2009-03-23 |
2018-02-21 |
Raindance Technologies, Inc. |
Manipulation von mikrofluidiktröpfchen
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
US10520500B2
(en)
|
2009-10-09 |
2019-12-31 |
Abdeslam El Harrak |
Labelled silica-based nanomaterial with enhanced properties and uses thereof
|
US20130079382A1
(en)
|
2009-10-12 |
2013-03-28 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
EP2517025B1
(de)
|
2009-12-23 |
2019-11-27 |
Bio-Rad Laboratories, Inc. |
Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
|
WO2011100604A2
(en)
|
2010-02-12 |
2011-08-18 |
Raindance Technologies, Inc. |
Digital analyte analysis
|
US9399797B2
(en)
|
2010-02-12 |
2016-07-26 |
Raindance Technologies, Inc. |
Digital analyte analysis
|
US10351905B2
(en)
|
2010-02-12 |
2019-07-16 |
Bio-Rad Laboratories, Inc. |
Digital analyte analysis
|
US9366632B2
(en)
|
2010-02-12 |
2016-06-14 |
Raindance Technologies, Inc. |
Digital analyte analysis
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスチレチン(TTR)関連眼アミロイドーシスのためのsiRNA療法
|
AU2011261434B2
(en)
|
2010-06-02 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2011160062A2
(en)
|
2010-06-17 |
2011-12-22 |
The Usa As Represented By The Secretary, National Institutes Of Health |
Compositions and methods for treating inflammatory conditions
|
US9562897B2
(en)
|
2010-09-30 |
2017-02-07 |
Raindance Technologies, Inc. |
Sandwich assays in droplets
|
CN103370054A
(zh)
|
2010-11-09 |
2013-10-23 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
WO2012065067A2
(en)
|
2010-11-12 |
2012-05-18 |
Georgetown University |
Immortalization of epithelial cells and methods of use
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
EP2648763A4
(de)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
|
SI2670411T1
(sl)
|
2011-02-02 |
2019-06-28 |
Excaliard Pharmaceuticals, Inc. |
Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
|
EP2670843B1
(de)
|
2011-02-03 |
2014-10-29 |
The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services |
Multivalente impfstoffe für tollwutvirus und filoviren
|
US9364803B2
(en)
|
2011-02-11 |
2016-06-14 |
Raindance Technologies, Inc. |
Methods for forming mixed droplets
|
WO2012112804A1
(en)
|
2011-02-18 |
2012-08-23 |
Raindance Technoligies, Inc. |
Compositions and methods for molecular labeling
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
JP2014511694A
(ja)
|
2011-04-03 |
2014-05-19 |
ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル |
修飾型rna(mod−rna)を使用する効率的なインビボタンパク質発現
|
US9951313B2
(en)
|
2011-06-02 |
2018-04-24 |
President And Fellows Of Harvard College |
Methods and uses for ex vivo tissue culture systems
|
DE202012013668U1
(de)
|
2011-06-02 |
2019-04-18 |
Raindance Technologies, Inc. |
Enzymquantifizierung
|
US8841071B2
(en)
|
2011-06-02 |
2014-09-23 |
Raindance Technologies, Inc. |
Sample multiplexing
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
AU2012272908A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
EP3366312A1
(de)
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Serpina 1 sirnas: materialzusammensetzungen und verfahren zur behandlung
|
WO2013003112A1
(en)
|
2011-06-27 |
2013-01-03 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
US8658430B2
(en)
|
2011-07-20 |
2014-02-25 |
Raindance Technologies, Inc. |
Manipulating droplet size
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
EP2780456A1
(de)
|
2011-11-17 |
2014-09-24 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Therapeutische rna schalter-zusammensetzungen und anwendungsverfahren dafür
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
BR112015006176B1
(pt)
|
2012-09-21 |
2023-04-18 |
Intensity Therapeutics, Inc |
Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
CA2918194C
(en)
|
2013-03-27 |
2022-12-06 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
EP2994167B1
(de)
|
2013-05-06 |
2020-05-06 |
Alnylam Pharmaceuticals, Inc. |
Dosierungen und verfahren zur abgabe von lipidformulierten nukleinsäuremolekülen
|
TW202003849A
(zh)
|
2013-10-02 |
2020-01-16 |
美商艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
MY197646A
(en)
|
2013-10-04 |
2023-06-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the alas1 gene
|
US11901041B2
(en)
|
2013-10-04 |
2024-02-13 |
Bio-Rad Laboratories, Inc. |
Digital analysis of nucleic acid modification
|
US9944977B2
(en)
|
2013-12-12 |
2018-04-17 |
Raindance Technologies, Inc. |
Distinguishing rare variations in a nucleic acid sequence from a sample
|
CN106061466A
(zh)
|
2013-12-19 |
2016-10-26 |
诺华股份有限公司 |
瘦蛋白mRNA组合物和制剂
|
US11193176B2
(en)
|
2013-12-31 |
2021-12-07 |
Bio-Rad Laboratories, Inc. |
Method for detecting and quantifying latent retroviral RNA species
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016054421A1
(en)
|
2014-10-02 |
2016-04-07 |
Protiva Biotherapeutics, Inc |
Compositions and methods for silencing hepatitis b virus gene expression
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
US11400139B2
(en)
|
2015-01-20 |
2022-08-02 |
The Children's Medical Center Corporation |
Anti-NET compounds for treating and preventing fibrosis and for facilitating wound healing
|
US10627340B2
(en)
|
2015-04-09 |
2020-04-21 |
Bikanta Corporation |
Imaging systems and methods using fluorescent nanodiamonds
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
US10485764B2
(en)
|
2015-07-02 |
2019-11-26 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
CA3205381A1
(en)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
EP3329003A2
(de)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur ausschaltung einer hepatitis-b-virus-genexpression
|
US10647981B1
(en)
|
2015-09-08 |
2020-05-12 |
Bio-Rad Laboratories, Inc. |
Nucleic acid library generation methods and compositions
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
US20170360815A1
(en)
|
2016-02-25 |
2017-12-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
US20170246262A1
(en)
|
2016-02-25 |
2017-08-31 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
EP3439695B1
(de)
|
2016-04-04 |
2022-05-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Multivalente impfstoffe gegen tollwut- und coronaviren
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
US11566061B2
(en)
|
2017-01-05 |
2023-01-31 |
Fred Hutchinson Cancer Center |
Systems and methods to improve vaccine efficacy
|
KR20200024793A
(ko)
|
2017-07-06 |
2020-03-09 |
애로우헤드 파마슈티컬스 인코포레이티드 |
알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
|
AU2018310857A1
(en)
|
2017-08-03 |
2020-02-13 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|
EP3788147A1
(de)
|
2018-05-04 |
2021-03-10 |
Tollys |
Tlr3-liganden, die sowohl epitheliale als auch myeloische zellen aktivieren
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
WO2020113135A1
(en)
|
2018-11-29 |
2020-06-04 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating rna
|
GB201910299D0
(en)
|
2019-07-18 |
2019-09-04 |
Aouadi Myriam |
Medical uses, methods and uses
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
CN117377763A
(zh)
|
2020-04-06 |
2024-01-09 |
阿尔尼拉姆医药品有限公司 |
用于沉默myoc表达的组合物和方法
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|